PROBLEMA VYBORA TROMBOLITIChESKOGO PREPARATA PRI OSTROM INFARKTE MIOKARDA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents a brief historical overview of the development of thrombolytic therapy for acute myocardial infarction and other information about the thrombolytic agents presented at the domestic pharmaceutical market. The results of studies comparing these drugs are discussed. Given the features of pharmacokinetics, pharmacodynamics and clinical effects, possible algorithms for the selection of thrombolytic agents in some clinical situations are suggested.

Full Text

Restricted Access

About the authors

E. V Vyshlov

Email: evv@cardio-tomsk.ru

References

  1. Mehta N.J., Khan I.A. Cardiology's 10 greatest discoveries of the 20th century. Tex. Heart Inst. J. 2002; 29: 164-71.
  2. Tillett W., Garner R. The fibrinolytic activity of hemolytic streptococci. J. Exp. Med. 1933; 58: 485-502.
  3. Christensen L.R. Streptococcal fibrinolysis: a proteolytic reaction due to a serum enzyme activated by streptococcal fibrinolysin. J. Gen. Physiol. 1945. Vol. 28. P. 363-83.
  4. Sherry S., Tillett W.S., Christensen L.R. Presence and significance of desoxyribosenucleoprotein in the purulent pleural exudates of patients. Proc. Soc. Exper. Biol.1948; 68: 179.
  5. Fletcher A.P., Alkjaersig N., Smyrniotis F.E., Sherry S. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans. Assoc. Am. Physicians 1958; 71: 287-96.
  6. Kenneth M.M. Effects of Intravenous Administration of Fibrinolysin (Plasmin) in Man. Circulation. 1959; 20: 42-55.
  7. Кудряшов Б.А. Проблемы свертывания крови и тромбообразования. М., 1960. 244 с.
  8. Innerfield I., Schwarz A., Angrist A. Intravenous trypsin: its anticoagulant, fibrinolytic and thrombolytic effects. J. Clin. Invest. 1952; 31: 1049-55.
  9. Innerfield I., Schwarz A., Angrist A. Parenteral administration of trypsin: clinical effect in 538 patients. JAMA. 1953; 152; 597-605.
  10. Братчик А.М. Клинические проблемы фибринолиза. Киев, 1993. 342 с.
  11. Чазов Е.И., Матвеева Л.С., Мазаева А.В. и др. Внутрикоронарное введение фибринолизина при остром инфаркте миокарда. Тер. архив. 1976; 4: 8-19.
  12. Марков В.А., Вышлов Е.В., Панфилова Е.В., Максимов И.В., Репин А.Н., Шиканков В.А., Крылов А.Л., Карпов Р.С. Сравнение эффективности стрептокинзы при болюсом и капельном введении у больных инфарктом миокарда. Кардиология. 2002; 9: 26-9.
  13. Дзизинский А.А., Гомазков О.А. Кинины в физиологии и патологии сердечно-сосудистой системы. Новосибирск, 1976. 206 с.
  14. Андреенко Г.В., Суворова А.В., Бесолицина Л.А., Саргин К.В. Кининовая система крови у больных острым инфарктом миокарда при лечении тромболитическими препаратами. Кардиология. 1977; 2: 70-4.
  15. Schroder R., Biamino G., von Leitner E., Linderer T. Intravenose Streptokinase - Infusion beim akutem Myokardinfarkt. Dtsch. Med. Wschr. 1981. Vol. 106. P. 294-97.
  16. Gruppo Italiano per lo Studio della Streptochinasi nell’infarcto myocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet / 1986; 1: 397-401.
  17. ISIS_II (Second International Study of Infarct Survival). Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction. Lancet. 1988; 2: 349-60.
  18. Granger C.B., White H.D., Bates E.R., Ohman E.M., Califf R.M. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am. J. Cardiol. 1994; 74; 1220-28.
  19. Granger C.B., Califf R.M., Topol E.J. Thrombolytic therapy for acute
  20. myocardial infarction: a review. Drugs. 1992; 44: 293-325.
  21. The GUSTO Investigator. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 1993; 389: 673-82.
  22. Van de Werf F., Topol E.L., Lee K.L., et al. Variations in patient management for acute myocardial infarction in the United States and other countries. Results from the GUSTO Trial. JAMA. 1995; 273: 1586-91.
  23. Eikelboom J.W., Mehta S.R., Pogue J., Yusuf S. Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials. Intracranial hemorrhage in trials of bolus thrombolytic therapy. JAMA. 2001; 285: 444-50.
  24. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N. Engl. J. Med. 1993; 329: 1615-22.
  25. Mark D.B., Hlatky M.A., Califf R.M., Naylor CD, Lee K.L., Armstrong P.W., Barbash G., White H., Simoons M.L., Nelson C.L. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N. Engl. J. Med. 1995; 332: 1418-24.
  26. Van de Werf F., Cannon C.P., Luyten A., Houbracken K., McCabe C.H., Berioli S., Bluhmki E., Sarelin H., Wang-Clow F., Fox N.L., Braunwald E. Safety assessment of single_bolus administration of TNK tissue_plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. Am. Heart J. 1999; 137: 786-91.
  27. Van de Werf. Assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) investigators. Single_bolus tenecteplase compared with front_ loaded alteplase in acute myocardial infarction. The ASSENT-2double_blind randomized trial. Lancet. 1999; 354: 716-722.
  28. Марков В.А., Вышлов Е.В., Севастьянова Д.С., Филюшкина В.Ю., Демьянов С.В., Даниленко А.М. Сравнительная эффективность стрептокиназы и тенектеплазы на догоспитальном этапе у больных инфарктом миокарда. Сибирский медицинский журнал (Томск). 2013; 2: 20-4.
  29. Староверов И.И., Коткин К.Л. Пуролаза -отечественный тромболитический препарат третьего поколения. Использование при остром инфаркте миокарда. РМЖ. 2004; 9: 3-7.
  30. Vanderschueren S., Barrio L., Kerdsinchai P., et al. A randomized trial of recombinant staphyloki-nase versus alteplase for coronary artery potency in acute myocardial infarction. Circulation. 1995. Vol. 92.P. 2044-49.
  31. Vanderschueren S., Dens J., Kerdsinchai P., et al. A pilot randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am Heart J. 1997. Vol. 134. P. 213-19.
  32. Vanderschueren S., Collen D., Van de Werf F. A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis. Thromb. Haemost. 1996; 76: 541-44.
  33. Маркин С.С., Семенов А.М., Марков В.А., Вышлов Е.В., Низов А.А., Аксентьев С.Б., Пономарев Э.А., Лебедев, П.А., Барбараш О.Л., Кашталап В.В. Исследование нового отечественного тромболитического препарата Фортелизин® у больных острым инфарктом миокарда. Сибирский медицинский журнал (Томск). 2012; 1: 27-32.
  34. Марков В.А., Маркин С.С., Семенов А.М., Беляков Н.А. Неиммуногенная стафилокиназа в лечении больных с острым инфарктом миокарда. Вопросы импортозамещения. Журнал международной медицины. 2014; 3: 5-10.
  35. Kunadian V., Gibson C.M. Thrombolytics and myocardial infarction. Cadriovasc. Therapeut. 2012; 30( 2): e81-e88.
  36. Кэмпбелл В.Ф. Международное руководство по инфаркту миокарда / Пер. с англ. В.М. Руда. М., 1997. 87 с.
  37. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2012; 33: 2569-19.
  38. https://www.clinicaltrials.gov/ct2/show/NCT023 01910?term=Fortelyzin&rank=1/ (12.07.2015)
  39. http://static-0.rosminzdrav.ru/ (12.07.2015)

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies